1-5 of 5
Jesse J Smith
Close
Sort by
Journal Articles

Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation

Michael J Thomenius, PhD BA, Jennifer Totman, Kat Cosmopoulos, Dorothy Brach, Lei Ci, Neil Farrow, Jesse J Smith, Richard Chesworth, Kenneth W. Duncan, Cuyue Tang, Thomas Riera, John Lampe
Journal: Blood
Blood (2018) 132 (Supplement 1): 3207.
https://doi.org/10.1182/blood-2018-99-110803
Published: 2018
Journal Articles

Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor

Elayne Chan-Penebre, Veronica Gibaja, John Campbell, Ogunbodede Olu, Elizabeth Admirand, Dorothy Brach, Cuyue Tang, Alejandra Raimondi, Tami Hood, Alexis Cocozaki, Sule Karaman, Kimberly Stickland, Christopher Plescia, Michael Munchhof, Kelli Armstrong, Thomas Riera, Stuart Orkin, Ann Boriack-Sjodin, William Janzen, Stephen Blakemore, Scott A Ribich, Richard Chesworth, Jesse J Smith, Kenneth W Duncan
Journal: Blood
Blood (2017) 130 (Supplement 1): 537.
https://doi.org/10.1182/blood.V130.Suppl_1.537.537
Published: 2017
Journal Articles

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Elayne Penebre, PhD, Kristy G Kuplast, Christina R Majer, L. Danielle Johnston, MS, Nathalie Rioux, PhD, Michael Munchhof, PhD, Lei Jin, PhD, P. Ann Boriak-Sjodin, PhD, Tim J Wigle, PhD, Suzanne L Jacques, PhD, Kip A West, PhD, Trupti Lingaraj, Kimberly Stickland, PhD, Scott A Ribich, PhD, Alejandra Raimondi, MS, Margaret Porter-Scott, PhD, Nigel J Waters, PhD, Roy M Pollock, PhD, Jesse J Smith, PhD, Olena Barbash, PhD, Ryan G. Kruger, PhD, Robert A Copeland, PhD, Mikel P Moyer, PhD, Richard Chesworth, DPhil, Kenneth W Duncan, PhD
Journal: Blood
Blood (2014) 124 (21): 438.
https://doi.org/10.1182/blood.V124.21.438.438
Published: 2014
Journal Articles

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models

L. Danielle Johnston, Sarah Knutson, PhD, Natalie Warholic, Christine R Klaus, Tim J. Wigle, PhD, Dorothy Iwanowicz, Bruce A. Littlefield, PhD, Margaret Porter Scott, PhD, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Roy M. Pollock, PhD, Kevin W Kuntz, PhD, Heike Keilhack, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 4416.
https://doi.org/10.1182/blood.V122.21.4416.4416
Published: 2013
Journal Articles

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL -Rearranged Leukemia Cells

Christine R Klaus, Scott R. Daigle, PhD, Dorothy Iwanowics, L. Danielle Johnston, Carly A Therkelsen, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Edward J Olhava, PhD, Margaret Porter Scott, PhD, Roy M. Pollock, PhD, Alejandra Raimondi
Journal: Blood
Blood (2013) 122 (21): 3930.
https://doi.org/10.1182/blood.V122.21.3930.3930
Published: 2013